EGFR and cancer: Furthermore, the conjugation of the anti-EGFR aptamer with the anti-CTLA-4mAb allowed also for the efficient killing of cancer cells mediated by effector and NK lymphocytes in co-cultures of tumor cells with both hPBMCs or NK cells, thus strongly increasing the cytotoxicity of the two partners in the chimeric construct.